Opinion
Video
Select Ongoing Trials for nccRCC and Impact on the Treatment Landscape
Author(s):
EP: 1.Treatment Selection in the Frontline Setting of Advanced Clear Cell RCC
EP: 2.Dr Wulff-Burchfield Reviews CheckMate 214 and CheckMate 9ER
EP: 3.Dr Xu Reviews Data from the CLEAR Trial and Recent Analyses at ASCO 2024 - Lenvatinib + Pembrolizumab in Frontline Advanced RCC
EP: 4.Dr Voss Shares Highlights from the COSMIC-313 and LITESPARK-024 Trials
EP: 5.Exciting Data and Trials in Progress from ASCO 2024
EP: 6.Ongoing RCC Clinical Trials that may Impact Practice
EP: 7.Dr Xu Provides Clinical Perspective on the CONTACT-03 Trial Outcomes
EP: 8.Dr Voss Application of Updated KEYNOTE-564 Data
EP: 9.Guiding Sequencing & Finding a Contemporary Regimen/ Approach to Treatment Post-Checkpoint Inhibition
EP: 10.World Health Organization (WHO) Classification Updates for Papillary RCC
EP: 11.Additional Forward-Looking Data and Studies Beyond Frontline Therapy in RCC
EP: 12.The Role of Chemotherapy in nccRCC Treatment
Now Viewing
EP: 13.Select Ongoing Trials for nccRCC and Impact on the Treatment Landscape
EP: 14.Final Thoughts/Looking Forward
- Please review ongoing trials for patients with nccRCC and discuss the potential impact of these studies on the treatment landscape.
- Phase 2 KEYNOTE-B61 trial, comparing len + pembro in 1L nccRCC
- Please provide a brief background surrounding KEYNOTE-B61
- Please discuss extended follow-up presented at ASCO GU 2024
- Phase 2 trial assessing nivo + cabo (
Related Videos
Related Content
